14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $64.16 $84.89 Friday, 3rd May 2024 ITCI stock ended at $68.80. This is 2.19% less than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 4.19% from a day low at $68.48 to a day high of $71.35.
90 days $62.78 $84.89
52 weeks $45.50 $84.89

Historical Intra-Cellular Therapies Inc. prices

Date Open High Low Close Volume
May 03, 2024 $71.07 $71.35 $68.48 $68.80 892 882
May 02, 2024 $73.77 $73.77 $70.01 $70.34 1 206 378
May 01, 2024 $71.61 $73.68 $71.61 $72.73 714 699
Apr 30, 2024 $72.45 $72.83 $71.38 $71.81 762 840
Apr 29, 2024 $73.58 $73.82 $71.97 $72.30 514 222
Apr 26, 2024 $72.27 $73.52 $71.66 $73.26 567 254
Apr 25, 2024 $72.46 $72.78 $71.35 $72.13 620 448
Apr 24, 2024 $73.74 $74.11 $72.41 $73.12 713 985
Apr 23, 2024 $75.06 $76.89 $73.69 $74.01 813 204
Apr 22, 2024 $73.68 $75.10 $72.02 $74.54 1 715 429
Apr 19, 2024 $72.31 $74.56 $70.94 $72.37 1 933 202
Apr 18, 2024 $74.40 $75.08 $71.21 $72.00 4 594 610
Apr 17, 2024 $79.00 $83.25 $76.50 $76.69 2 524 522
Apr 16, 2024 $75.29 $84.89 $75.00 $79.84 7 317 021
Apr 15, 2024 $65.71 $66.05 $64.16 $64.76 492 999
Apr 12, 2024 $67.63 $67.89 $64.84 $65.88 573 953
Apr 11, 2024 $67.89 $68.68 $66.53 $67.97 430 671
Apr 10, 2024 $67.12 $67.57 $66.53 $67.28 541 271
Apr 09, 2024 $68.07 $68.97 $67.91 $68.62 472 577
Apr 08, 2024 $68.74 $68.91 $67.33 $67.70 269 778
Apr 05, 2024 $67.29 $69.49 $67.05 $68.44 628 257
Apr 04, 2024 $68.49 $69.33 $66.61 $67.21 635 169
Apr 03, 2024 $66.28 $68.73 $65.99 $67.32 527 358
Apr 02, 2024 $66.94 $66.95 $65.93 $66.67 481 424
Apr 01, 2024 $69.20 $69.36 $67.73 $68.27 356 025
Click to get the best stock tips daily for free!

About Intra-Cellular Therapies Inc.

Intra-Cellular Therapies. Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as ... ITCI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT